

## Main Organizing Committee

Anne Juppo (chairman), Outi Salminen (vice chairman), Leena Peltonen (scientific secretary), Merja Voutilainen (treasurer), Ville Aalto-Setälä, Jyrki Heinämäki, Astrid Subrizi, Niina Suni, Päivi Tammela

## National Scientific Advisory Board

Bert van Veen (Orion), Olli Oksala (Santen), Pirjo Kortesoja (Bayer-Schering Pharma), Nina Sevón-Vilkman (The Pharmaceutical Learning Centre), Mikko Unkila and Veli-Matti Lehtola (Hormos Medical), Mia Bengtström (Pharma Industry Finland), Marjo-Riitta Helle (National Agency for Medicines), Professors of the Faculty of Pharmacy (University of Helsinki)

## Abstracts

Scientific contributions are welcomed. The majority of the short communications will be presented as posters and, according to decision of the Organizing Committee, there are also a few oral communications. Abstracts must be submitted no later than January 31, 2008.

## Registration

[www.hdr.fi](http://www.hdr.fi)

On-line registration will be opened in November 2007.

## HDR 2008 Congress Secretariat

**Congreszon Oy**

Itälahdenkatu 22 A, FI-00210 Helsinki, Finland

Tel. +358 9 5840 9350

Fax +358 9 5840 9555

Contact: [hdr08@congreszon.fi](mailto:hdr08@congreszon.fi)

## Finland

Finland is a beautiful northern country that has about 5.3 million inhabitants. It is an advanced society with a high level of education and technology. The capital of the country is Helsinki. About 2/3 of Finland's surface is covered by forest and there are more than 200 000 lakes. The coastal archipelago with its labyrinth of waterways is unique. The stable and safe society, clean environment and scenic nature make the country a pleasant place to visit.



HELSINKI **DRUG RESEARCH** 2008



EUROPEAN FEDERATION  
FOR PHARMACEUTICAL  
SCIENCES



HELSINKI **DRUG RESEARCH** 2008

## HDR 2008

**19th Helsinki Drug Research 2008**


### Organizers:

Faculty of Pharmacy, University of Helsinki, Finland  
The Finnish Pharmaceutical Society

June 9-11, 2008  
Biomedicum Helsinki  
Finland

HDR 2008 is a multidisciplinary scientific meeting with six symposia covering selected areas of drug development and use.

[www.hdr.fi](http://www.hdr.fi)



UNIVERSITY OF HELSINKI

# HELSINKI DRUG RESEARCH 2008 SYMPOSIA

## **Pharmaceutical Manufacturing Research**

This symposium will cover current topics and developments in pharmaceutical manufacturing research (PMR). In addition, trends in Process Analytical Technology and challenges related to process induced transformations will be discussed. The following topics will be highlighted: application of ultrasound in PMR, online imaging of tablets, electrostatic phenomena in pharmaceutical processes, aqueous-based film coating, and crystallisation and particle engineering.

## **Green Technologies and Process Engineering**

Symposium focuses in latest advances in Green Technologies and Green Process Engineering especially from Pharmaceutical Industry point of view. The following key topics will be highlighted: "green solvent"-based and solvent-free pharmaceutical manufacturing processes, rational process design (including experimental design, optimisation and intensification using mini / micro devices), packaging, risk management and safety issues and a new EU regulatory framework for Registration, Evaluation and Authorisation of Chemicals (REACH).

## **Recent Technologies in Metabolomics, Lipidomics and Proteomics**

Symposium focuses on recent research and developments in metabolomics, lipidomics and proteomics. The programme consists lectures on novel approaches for small molecule, peptide and protein detection by mass spectrometry and nuclear magnetic resonance spectroscopy, data analysis, modeling and applications in drug research, diagnostics and life science.

## **Nano- and Microtechnology in Pharmacy**

There is increasing optimism, that nanotechnology applied to medicine will bring significant advances in the diagnosis and treatment of disease. This two-day symposium features some current innovative applications of nanotechnology including nanoparticulate delivery systems, nanocrystallizing processes, micro- and nanofluidics and microreactors.

## **Treatment of Parkinson's Disease: Key Findings during the Last 20 Years**

Drug therapy of Parkinson's disease (PD) has been stabilized to a gold standard comprising of L-dopa (LD) and peripheral dopa decarboxylase (DDC) inhibitors. This dual therapy might be soon universally replaced by a triple therapy: LD + DDC-inhibitor + COMT inhibitor. Also, the early use of dopamine agonists has been adopted to delay the initiation of the LD therapy. High hopes have been put to neuroprotective and neurorestorative therapies. The victories, some of them of Finnish origin, and challenges of the future therapy of PD are reviewed in this symposium.

## **Core Competences in Pharmacoeconomics**

This symposium considers the relationship between drug costs and benefits from the viewpoint of both industry and public sector. Both industry and public sector need skills for pharmacoeconomic analysis. These required skills are considered. Also the latest methods and research of pharmacoeconomics are presented.

FOR MORE INFORMATION PLEASE VISIT [www.hdr.fi](http://www.hdr.fi)